The advent of AI is changing how drugs are developed by predicting likely outcomes without extensive testing. While drug companies seem hesitant to test-drive this tech, they'll likely eventually warm ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

High-rolling investors have positioned themselves bullish on Recursion Pharmaceuticals (NASDAQ:RXRX), and it's important for retail traders to take note. \This activity came to our attention today ...

Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like. It'll take a few ...

Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug Administration ...